CliffBio
biologic

Stelara

ustekinumab

Loss of exclusivitySeptember 2028projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →View the full company profile on CliffBio

Drug detail

Brand nameStelara
Active ingredientustekinumab
Strength130MG/26ML (5MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2016
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Stelara patent cliff — loss of exclusivity September 2028 | CliffBio